AGAP2 and prostate carcinoma: In conclusion, the key findings of our study presented evidence suggesting that the down-regulation of lncRNA AGAP2-AS1 inhibited PDLIM5 expression, which ultimately impedes prostate cancer development and progression through up-regulating miR-195-5p expression (Figure 7).